ReviewBlood advances2024
The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas.
Review in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Pooled it
- Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.American journal of hematology · 2026Trial
- Three-year follow-up of epcoritamab therapy in Japanese patients with relapsed/refractory follicular lymphoma in EPCORE NHL-3.International journal of hematology · 2026Trial
- Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Trial Watch - bispecific T cell engagers and higher-order multispecific immunotherapeutics.Oncoimmunology · 2026Review
- Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.Current oncology reports · 2026Review
- CD20 × CD3 Bispecific Antibodies in B-Cell Non-Hodgkin Lymphomas: Current Evidence, Therapeutic Integration, and Future Directions.Medicina (Kaunas, Lithuania) · 2026Review
- Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22.Research square · 2026Article
- T-Cell-Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions.European journal of haematology · 2026Review
- Case Report: Targeted interleukin-6 blockade by siltuximab for cytokine release syndrome control and infection limitation in thirteen patients treated with bi-specific T-cell engagers.Frontiers in immunology · 2026Article
- Advances and future perspectives in chimeric antigen receptor T-cell and bispecific antibody therapies for multiple myeloma.Journal of clinical and experimental hematopathology : JCEH · 2025Review
- Article
- A Large Room for Improvement in the Management of Relapsed/Refractory Large B-Cell Lymphoma in Türkiye: Real-World Outcomes in a Setting Without Access to T-Cell Redirecting TherapiesTurkish journal of haematology : official journal of Turkish Society of Haematology · 2025Article
- Fifty years of monoclonals: the past, present and future of antibody therapeutics.Nature reviews. Immunology · 2025Article
- Development of VNX-101, an adeno-associated virus with less immunogenicity and efficient long-term expression of a CD19 T cell engager.Molecular therapy. Methods & clinical development · 2025Article
- Adjusting the scope of natural killer cells in cancer therapy.Cellular & molecular immunology · 2025Review
- Review
- Editorial: Innovative immunotherapy strategies for enhanced treatment of Hodgkin and non-Hodgkin lymphomas.Frontiers in immunology · 2025Article
- Celebrating a year of immunotherapy/cell and gene therapy in Blood Advances.Blood advances · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractT-cell engaging-therapies have transformed the treatment landscape of relapsed and refractory B-cell non-Hodgkin lymphomas by offering highly effective treatments for patients with historically limited therapeutic options. This review focuses on the advances in chimeric antigen receptor-modified T cells and bispecific antibodies, first providing an overview of each product type, followed by exploring the primary data for currently available products in large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. This review also highlights key logistical and sequencing considerations across diseases and product types that can affect clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.